A trial where neither the patients nor the doctors know who is getting the real treatment and who is getting placebo, so expectations cannot sway the results.
Also called: double blind, blinded, masked trial, double-masked
Estimates vary with how cases are counted. Research funded by Crohn's & Colitis UK found about 1 in 123 people in the UK live with Crohn's or colitis, over half a million people. A large GP-records study found about 276 in every 100,000 people had Crohn's at the end of 2018, with new cases in teenagers almost doubling.
Is a pill camera (capsule endoscopy) safe if I might have Crohn's?
The main risk is the capsule getting stuck in a narrowed section of bowel. One NHS leaflet puts this at about 1 to 2 in 100 for bleeding checks, possibly 4 to 5 in 100 with Crohn's. Crohn's & Colitis UK says you may first be given a dissolvable dummy 'patency' capsule to check the way is clear. Biopsies cannot be taken with a capsule.
The Lancet Gastroenterology & HepatologyStudyJan 2022Patients and professionals
A small pilot trial of 44 adults with mild to moderate Crohn's who had not had biologics. The CDED, with or without supplement drinks, put more than half into remission at 6 weeks, and most of them were still in remission at 24 weeks. About a third had a healed bowel lining. The authors say a bigger trial is needed before firm conclusions.
New England Journal of MedicineStudyFeb 2004Patients and professionals
A trial in people with Crohn's fistulas (abnormal tunnels, often around the anus) who had responded to infliximab. Carrying on with infliximab every 8 weeks kept people well for much longer than switching to a dummy drug. At one year, 36% on infliximab had no draining fistulas, against 19% on placebo.
The main international trial of risankizumab injections to keep Crohn's under control after a good response to drip treatment. More people who stayed on risankizumab remained in remission and had gut healing than those switched to placebo, and side effects were similar between groups.
New England Journal of MedicineStudyNov 2016Patients and professionals
The trials that led to ustekinumab (Stelara) being used for Crohn's. A first drip of ustekinumab helped more people improve than a dummy drip, and injections every 8 or 12 weeks afterwards kept about half of responders in remission at week 44, against about 36% on placebo. Side effects were similar between groups.
CochraneSystematic reviewNov 2021Patients and professionals
Tummy pain often continues in Crohn's even when inflammation is under control. This review looked for treatments aimed at the pain itself but found so few, small studies that no conclusions could be drawn.
A detailed guide to the tests used to diagnose and monitor Crohn's and colitis: blood tests (full blood count, CRP, liver and kidney tests), poo tests including faecal calprotectin and FIT, endoscopies with tips on bowel prep, capsule endoscopy and the dummy patency capsule, and X-rays, CT, MRI and ultrasound. It explains what results can and cannot tell you, for example that calprotectin can be normal during a flare in the small bowel.